Drug Information
General Information | ||||||
---|---|---|---|---|---|---|
Drug ID |
DR01519
|
|||||
Drug Name |
Cefuroxime axetil
|
|||||
Synonyms |
cefuroxime axetil; Ceftin; Zinnat; Elobact; Zinat; Cefuroxime 1-acetoxyethyl ester; Bioracef; CXM-AX; Coliofossim; Furoxime; Cetoxil; Celocid; Cethixim; Nivador; Medoxm; Kalcef; Zoref; Sharox-500; UNII-Z49QDT0J8Z; DRG-0157; SN 407; CCI 15641; CCI-15641; Cepazine; CCI 1564; BRN 6854419; Z49QDT0J8Z; CHEBI:3516; (RS)-1-Hydroxyethyl (6R,7R)-7-(2-(2-furyl)glyoxylamido)-3-(hydroxymethyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylate, 7(sup 2)-(Z)-(O-methyloxime), 1-acetate 3-carbamate; C20H22N4O10S; Cefazine; Altacef
|
|||||
Indication | Bacterial infections [ICD11: 1A00-1H0Z] | Approved | [1] | |||
Structure |
|
|||||
3D MOL | 2D MOL | |||||
Formula |
C20H22N4O10S
|
|||||
Canonical SMILES |
CC(OC(=O)C)OC(=O)C1=C(CSC2N1C(=O)C2NC(=O)C(=NOC)C3=CC=CO3)COC(=O)N
|
|||||
InChI |
InChI=1S/C20H22N4O10S/c1-9(25)33-10(2)34-19(28)15-11(7-32-20(21)29)8-35-18-14(17(27)24(15)18)22-16(26)13(23-30-3)12-5-4-6-31-12/h4-6,10,14,18H,7-8H2,1-3H3,(H2,21,29)(H,22,26)/b23-13-/t10?,14-,18-/m1/s1
|
|||||
InChIKey |
KEJCWVGMRLCZQQ-YJBYXUATSA-N
|
|||||
CAS Number |
CAS 64544-07-6
|
|||||
Pharmaceutical Properties | Molecular Weight | 510.5 | Topological Polar Surface Area | 214 | ||
Heavy Atom Count | 35 | Rotatable Bond Count | 12 | |||
Hydrogen Bond Donor Count | 2 | Hydrogen Bond Acceptor Count | 12 | |||
XLogP |
0.9
|
|||||
PubChem CID | ||||||
ChEBI ID |
CHEBI:3516
|
|||||
DT(s) Transporting This Drug | PEPT1 | Transporter Info | Peptide transporter 1 | Substrate | [2] | |
References | ||||||
1 | Cefuroxime axetil was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
2 | Intestinal transport of beta-lactam antibiotics: analysis of the affinity at the H+/peptide symporter (PEPT1), the uptake into Caco-2 cell monolayers and the transepithelial flux. Pharm Res. 1999 Jan;16(1):55-61. |
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.